Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 9/20 | 0.33 |
| ▸ | MMP1 | P03956 | 8/20 | 0.33 |
| ▸ | MMP9 | P14780 | 6/20 | 0.33 |
| ▸ | MMP13 | P45452 | 6/20 | 0.33 |
| ▸ | MMP3 | P08254 | 5/20 | 0.33 |
| ▸ | MMP8 | P22894 | 5/20 | 0.33 |
| ▸ | MMP7 | P09237 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.32 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6945464 | 0.84 | PLA2G7 (0.49) | PLA2G7POLBMMP2MMP1MMP9 | |
| SCHEMBL1593903 | 0.79 | PLA2G7 (0.45) | PLA2G7POLBMMP2MMP1MMP9 | |
| SCHEMBL419379 | 0.79 | F2 (0.48) | PLA2G7POLBMMP2MMP1MMP9 | |
| SCHEMBL12600734 | 0.77 | PLA2G7 (0.46) | PLA2G7POLBMMP2MMP1MMP9 | |
| SCHEMBL7040815 | 0.77 | PLA2G7 (0.50) | PLA2G7POLBMMP2MMP1MMP9 | |
| SCHEMBL7518193 | 0.77 | PLA2G7 (0.50) | PLA2G7POLBMMP2MMP1MMP9 | |
| SCHEMBL940892 | 0.77 | PLA2G7 (0.40) | PLA2G7MMP2MMP1MMP9MMP13 | |
| SCHEMBL12692931 | 0.76 | PLA2G7 (0.49) | PLA2G7POLBMMP2MMP1MMP9 | |
| SCHEMBL422413 | 0.76 | PLA2G7 (0.49) | PLA2G7POLBMMP2MMP1MMP9 | |
| SCHEMBL7448180 | 0.75 | PLA2G7 (0.42) | PLA2G7MMP2MMP1MMP9MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6031103-A | Process for manufacturing 1-[3-cyclopentyl -2(R)-[1(R)-hydroxycarbamoyl)-2-(3, 4, 4-trimethyl -2, 5-D ioxo-1-imidazolidinyl) ethyl] propionyl] piperidine | HOFFMANN-LA ROCHE INC. (US) | 2000-02-29 | — | — | US | claimed |
| EP-0816341-A1 | Process for the preparation of chiral succinic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-01-07 | — | — | EP | claimed |
| JP-10087633-A | — | — | None | — | — | JP | disclosed |
| EP-1918278-A1 | Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases | Novartis AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| EP-1052249-B1 | Process for the preparation of hydroxamic acids | HOFFMANN LA ROCHE (CH) | 2003-08-13 | — | — | EP | disclosed |
| US-6452010-B1 | HYDROXAMIC ACID DERIVATIVES OF CERTAIN CARBOXYLIC ACIDS HAVE BEEN RECOGNIZED AS INHIBITORS OF MATRIX METALLOPROTEINASES | HOFFMANN-LA ROCHE INC. | 2002-09-17 | — | — | US | disclosed |
| US-6410580-B1 | ANTIINFLAMMATORY AGENTS, RHEUMATIC DISEASES | NOVARTIS AG (CH) | 2002-06-25 | — | — | US | disclosed |
| US-6350885-B1 | TREATMENT OF MULTIPLE SCLEROSIS, ATHEROSCLEROTIC PLAQUE RUPTURE, AORTIC ANEURYSM, HEART FAILURE, LEFT VENTRICULAR DILATION, RESTENOSIS, PERIODONTAL DISEASE, CORNEAL ULCERATION, TREATMENT OF BURNS, DECUBITAL ULCERS, WOUND HEALING AGENT | WARNER-LAMBERT COMPANY | 2002-02-26 | — | — | US | disclosed |
| US-6316633-B1 | CARTILAGE PROTECTIVE AGENTS AND USEFUL IN THE THERAPY AND PROPHYLAXIS OF DEGENERATIVE JOINT DISEASES SUCH AS ATHEROSCLEROSIS | HOFFMAN-LA ROCHE INC. | 2001-11-13 | — | — | US | disclosed |
| US-6277987-B1 | FOR INHIBITING MATRIX-DEGRADING METALLOPROTEINASES IN MAMMALS | NOVARTIS AG (CH) | 2001-08-21 | — | — | US | disclosed |
| US-6197995-B1 | INTERMEDIATES FOR CARTILAGE PROTECTIVE AGENTS USEFUL IN TREATMENT AND PREVENTION OF DEGENERATIVE JOINT DISEASES SUCH AS ATHEROSCLEROSIS | HOFFMAN-LA ROCHE INC. | 2001-03-06 | — | — | US | disclosed |
| US-5698690-A | COLLAGENASE INHIBITORS; TREATMENT OF DEGENERATIVE JOINT DISEASES | HOFFMANN-LA ROCHE INC. (US) | 1997-12-16 | — | — | US | disclosed |
| US-5614625-A | COLLAGENASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 1997-03-25 | — | — | US | disclosed |
| EP-0763013-A1 | HYDROXYLAMINE DERIVATIVES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-03-19 | — | — | EP | disclosed |
| WO-1995033731-A1 | HYDROXAMIC ACID DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 1995-12-14 | — | — | WO | disclosed |
| WO-1995033709-A1 | HYDROXYLAMINE DERIVATIVES AND THEIR USE AS METALLOPROTEINASE INHIBITING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 1995-12-14 | — | — | WO | disclosed |
| EP-0684240-A1 | Hydroxamic acid derivatives with tricyclic substitution | F. HOFFMANN-LA ROCHE AG (CH) | 1995-11-29 | — | — | EP | disclosed |
| US-5447929-A | Collagenase inhibitors for degenerative joint disease, antitumor agents or atherosclerosis | HOFFMANN-LA ROCHE INC. (US) | 1995-09-05 | — | — | US | disclosed |
| US-5318964-A | Collangenase inhibitors; antiarthritic and -tumor agents; rheumatic diseases; osteoarthritis; atherosclerosis; multiple sclerosis | HOFFMANN-LA ROCHE INC. (US) | 1994-06-07 | — | — | US | disclosed |
| EP-0574758-A1 | Hydroxamic acid derivatives as collagenase inhibitors | F. HOFFMANN-LA ROCHE AG (CH) | 1993-12-22 | — | — | EP | disclosed |